ArticleTranslational pediatrics2026
The potential role of pan-immune-inflammation value in differentiating pediatric osteomyelitis from soft tissue infections.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Distinguishing between pediatric osteomyelitis (OM) and soft tissue infection (STI) remains a diagnostic challenge due to overlapping clinical and laboratory features. The pan-immune-inflammation value (PIV) is a new comprehensive biomarker calculated from counts of blood cells taken from outside the main part of the body, showing the overall condition of the immune system and inflammation in the body. This study aimed to evaluate the diagnostic utility of PIV in differentiating OM from STI in children. Methods: The retrospective study conducted a review of past data involving children who visited Department of Orthopedics, Center for Children's Health, Capital Medical University from January 2020 to May 2025. The cohort consisted of 59 children with OM and 310 with STI. Demographic, clinical, and laboratory parameters were systematically collected for all participants. PIV was calculated and analyzed. Results: The OM group showed higher PIV levels compared to the STI group (512.6±198.4 Conclusions: PIV is a promising, readily available biomarker that shows potential to effectively differentiate pediatric OM from STIs, potentially aiding in early diagnosis and appropriate management upon further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.